On a scale of 0 to 100, Clovis Oncology holds a
performance score of 4. The firm shows a Beta (market volatility) of 2.1057, which signifies a somewhat significant risk relative to the market. Let's try to break down what Clovis's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Clovis Oncology will likely underperform. Although it is vital to follow
Clovis Oncology historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy towards foreseeing
future performance of any stock is to evaluate the business as a whole together with its past performance, including all
available fundamental and
technical indicators. We have found twenty-one
technical indicators for Clovis Oncology, which you can use to evaluate the performance of the firm. Please makes use of Clovis Oncology
coefficient of variation,
maximum drawdown, as well as the
relationship between the Maximum Drawdown and
skewness to make a quick decision on whether Clovis Oncology
price patterns will revert.
The performance of Clovis Oncology in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Clovis Oncology's
stock prices. When investing in Clovis Oncology, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Clovis Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Clovis Oncology carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
Watch out for price decline
Please consider monitoring Clovis Oncology on a daily basis if you are holding a position in it. Clovis Oncology is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Clovis Oncology stock to be traded above the $1 level to remain listed. If Clovis Oncology stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Clovis Oncology's Liquidity
Clovis Oncology
financial leverage refers to using borrowed capital as a funding source to finance Clovis Oncology ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Clovis Oncology financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Clovis Oncology's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Clovis Oncology's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Clovis Oncology's total debt and its cash.
Another angle On Clovis Oncology
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Clovis Oncology has an asset utilization ratio of 20.32 percent. This connotes that the company is making $0.2 for each dollar of assets. An increasing asset utilization means that Clovis Oncology is more efficient with each dollar of assets it utilizes for everyday operations.
Our perspective of the latest Clovis Oncology spike
Latest downside variance is at 91.52.
As of the 2nd of July, Clovis Oncology shows the Downside Deviation of 9.57,
risk adjusted performance of 0.176, and Mean Deviation of 8.85. Clovis Oncology
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen
technical drivers for Clovis Oncology, which can be compared to its rivals. Please confirm
Clovis Oncology coefficient of variation,
maximum drawdown, as well as the
relationship between the Maximum Drawdown and
skewness to decide if Clovis Oncology is priced correctly, providing market reflects its regular price of 2.85 per share. Please also double-check Clovis Oncology
total risk alpha, which is currently at 3.35 to validate the company can sustain itself at a future point.
Our Final Takeaway
While many other companies under the biotechnology industry are still a bit expensive, Clovis Oncology may offer a potential longer-term growth to retail investors. In closing, as of the 2nd of July 2022, we believe Clovis Oncology is currently
undervalued. It hyperactively responds to market trends and projects
high probability of bankruptcy in the next two years. Our concluding 90 days buy vs. sell advice on the enterprise is
Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Clovis Oncology. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com